Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3 Use of the 2013 guidelines for the appropriate use of G-CSFs, version 2, published by the JSCO

From: A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors

  n = 301
Q9. Do you know the JSCO guidelines are available on the web?
 Yes 228 (75.7)a
 No 73 (24.3)
Q10. How did you learn that the JSCO guidelines are available on a web? (multiple choice)
 Academic meeting, study group meeting, workshop 182 (60.5)
 Medical personnel 118 (39.2)
 Academic journal, article 21 (7.0)
 Website 124 (41.2)
 Drug industry 44 (14.6)
 Others 3 (1.0)
Q11. Are the JSCO guidelines useful for the actual work of pharmacists?
 Very useful 168 (55.8)
 Useful to some extent 127 (42.2)
 Not so useful 6 (2.0)
 Useless 0 (0.0)
Q12. How often do you refer to the JSCO guidelines?
 Always 34 (11.3)
 Usually 121 (40.2)
 Sometimes 131 (43.5)
 Seldom 15 (5.0)
Q13. Is there any difference between JSCO guideline and the actual work of pharmacists?
 Not at all 125 (41.6)
 Somewhat different 162 (53.8)
 Considerably difference 13 (4.3)
 Completely different 1 (0.3)
Q14. To the Q13. which chose “it is totally considerably slightly different with the difference with the difference” by a question. What kind of difference was it?
 Usage of the prophylaxic administration of G-CSFs 23
 A pharmacist is not involved in the administration of G-CSFs 19
 It is difficult to fit a real patient 15
 Usage of no exothermicity neutropenia 11
 There is not consensus in the nosocomial G-CSFs usage 9
 The update of guidelines is late 5
 It is different from the usage of the package insert 5
 About the risk classification of the cancer chemotherapy regimen 4
 Usage of the remedial dosage 4
 Others 11
  1. JSCO Japan Society of Clinical Oncology, G-CSF Granulocyte-Colony Stimulating Factor
  2. aNumber (percent)